BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8645610)

  • 1. Metabolism of the cell differentiating agent 1alpha,25(OH)2-16-ene-23-yne vitamin D3 by leukemic cells.
    Satchell DP; Norman AW
    J Steroid Biochem Mol Biol; 1996 Jan; 57(1-2):117-24. PubMed ID: 8645610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1alpha,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells.
    Siu-Caldera ML; Clark JW; Santos-Moore A; Peleg S; Liu YY; Uskoković MR; Sharma S; Reddy GS
    J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):405-12. PubMed ID: 9010346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3 and 1alpha,25-dihydroxy-16-ene-23-yne-20-epi-vitamin D3: analogs of 1alpha,25-dihydroxyvitamin D3 that resist metabolism through the C-24 oxidation pathway are metabolized through the C-3 epimerization pathway.
    Reddy GS; Rao DS; Siu-Caldera ML; Astecker N; Weiskopf A; Vouros P; Sasso GJ; Manchand PS; Uskokovic MR
    Arch Biochem Biophys; 2000 Nov; 383(2):197-205. PubMed ID: 11185554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice.
    Zhou JY; Norman AW; Chen DL; Sun GW; Uskokovic M; Koeffler HP
    Proc Natl Acad Sci U S A; 1990 May; 87(10):3929-32. PubMed ID: 2339131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog.
    Aparna R; Subhashini J; Roy KR; Reddy GS; Robinson M; Uskokovic MR; Venkateswara Reddy G; Reddanna P
    J Cell Biochem; 2008 Aug; 104(5):1832-42. PubMed ID: 18348265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-function studies on analogues of 1 alpha,25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption.
    Norman AW; Zhou JY; Henry HL; Uskokovic MR; Koeffler HP
    Cancer Res; 1990 Nov; 50(21):6857-64. PubMed ID: 2208153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antiproliferative effects of 25-hydroxy-16-ene-23-yne-vitamin D₃ that resists the catalytic activity of both CYP27B1 and CYP24A1.
    Rhieu SY; Annalora AJ; LaPorta E; Welsh J; Itoh T; Yamamoto K; Sakaki T; Chen TC; Uskokovic MR; Reddy GS
    J Cell Biochem; 2014 Aug; 115(8):1392-402. PubMed ID: 24535953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of 1alpha,25(OH)2D3 and its 20-epi analog integrates clonal expansion, maturation and apoptosis during HL-60 cell differentiation.
    Campbell MJ; Drayson MT; Durham J; Wallington L; Siu-Caldera ML; Reddy GS; Brown G
    Mol Cell Endocrinol; 1999 Mar; 149(1-2):169-83. PubMed ID: 10375029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biological activities of 1alpha,25-dihydroxyvitamin D3 and its synthetic analog 1alpha,25-dihydroxy-16-ene-vitamin D3 in normal human osteoblastic cells and human osteosarcoma SaOS-2 cells are modulated by 17-beta estradiol and dependent on stage of differentiation.
    Rao LG; Liu LJ; Rawlins MR; McBroom RJ; Murray TM; Reddy GS; Uskokovic MR; Rao DS; Sutherland MK
    Biol Pharm Bull; 2001 Mar; 24(3):242-8. PubMed ID: 11256478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antiproliferative activity of 1alpha,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific.
    Zhao J; Tan BK; Marcelis S; Verstuyf A; Bouillon R
    J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):197-202. PubMed ID: 8645629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue specific metabolism of 1alpha,25-dihydroxy-20-epi-vitamin D3 into new metabolites with significant biological activity: studies in rat osteosarcoma cells (UMR 106 and ROS 17/2.8).
    Siu-Caldera ML; Rao DS; Astecker N; Weiskopf A; Vouros P; Konno K; Fujishima T; Takayama H; Peleg S; Reddy GS
    J Cell Biochem; 2001; 82(4):599-609. PubMed ID: 11500938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1 alpha,25-dihydroxyvitamin D3 analogs: structure-function relationships.
    Bischof MG; Redlich K; Schiller C; Chirayath MV; Uskokovic M; Peterlik M; Cross HS
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1254-60. PubMed ID: 8531089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
    Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
    Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-25 hydroxylation of 1alpha,24(R)-dihydroxyvitamin D3 is catalyzed by 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1): metabolism studies with human keratinocytes and rat recombinant CYP24A1.
    Astecker N; Bobrovnikova EA; Omdahl JL; Gennaro L; Vouros P; Schuster I; Uskokovic MR; Ishizuka S; Wang G; Reddy GS
    Arch Biochem Biophys; 2004 Nov; 431(2):261-70. PubMed ID: 15488475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of selective 20-epi-vitamin D
    Flarakos CC; Weiskopf A; Robinson M; Wang G; Vouros P; Sasso GJ; Uskokovic MR; Reddy GS
    Steroids; 2017 Mar; 119():18-30. PubMed ID: 28089927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of analogs of 1,25(OH)2 vitamin D3 on the proliferation and differentiation of the human chronic myelogenous leukemia cell line, RWLeu-4.
    Clark JW; Posner MR; Marsella JM; Santos A; Uskokovic M; Eil C; Lasky SR
    J Cancer Res Clin Oncol; 1992; 118(3):190-4. PubMed ID: 1372318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential activities of 1alpha,25-dihydroxy-16-ene-vitamin D(3) analogs and their 3-epimers on human promyelocytic leukemia (HL-60) cell differentiation and apoptosis.
    Nakagawa K; Sowa Y; Kurobe M; Ozono K; Siu-Caldera ML; Reddy GS; Uskokovic MR; Okano T
    Steroids; 2001; 66(3-5):327-37. PubMed ID: 11179741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
    Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
    Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia.
    Jung SJ; Lee YY; Pakkala S; de Vos S; Elstner E; Norman AW; Green J; Uskokovic M; Koeffler HP
    Leuk Res; 1994 Jun; 18(6):453-63. PubMed ID: 8207963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 25-Dehydro-1alpha-hydroxyvitamin D3-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change.
    Bula CM; Bishop JE; Ishizuka S; Norman AW
    Mol Endocrinol; 2000 Nov; 14(11):1788-96. PubMed ID: 11075812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.